Good afternoon. Welcome to Sage Therapeutics’ Third Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the ...
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -0.66% and 7.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago.